Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company focused on rare diseases, with news flow centered on its clinical programs, scientific publications, and corporate developments. The company’s updates frequently highlight progress with its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), and its proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform.
Investors following QNCX news can expect regular announcements on the pivotal Phase 3 NEAT clinical trial of eDSP in Ataxia-Telangiectasia (A-T), including milestones such as completion of enrollment, last patient last visit, safety reviews by an independent data and safety monitoring board, and plans for topline data. Quince also issues press releases on related open label extension studies, pediatric investigational plans, and preparation for potential regulatory submissions.
Beyond trial status, Quince’s news includes peer-reviewed publications and conference presentations. Recent communications have described early-stage clinical studies of eDSP in pulmonary and inflammatory bowel disorders, population pharmacokinetic modeling in A-T, and analyses of patient-reported walking capacity in children with A-T. These items provide scientific context for the company’s approach to erythrocyte-based corticosteroid delivery.
Corporate and financial updates are another key component of QNCX coverage. The company reports quarterly financial results, financing transactions, amendments to its European Investment Bank credit facility, and strategic relationships such as its agreement with Option Care Health to support potential commercial launch of eDSP in the United States. Quince also announces participation in healthcare conferences, investor days, and rare disease summits, where management discusses development plans, regulatory strategy, and potential pipeline expansion.
This news page aggregates these clinical, scientific, regulatory, and corporate disclosures so that readers tracking Quince Therapeutics and QNCX stock can review the company’s latest rare disease developments in one place.
Summary not available.
Summary not available.
Summary not available.
Quince Therapeutics, Inc. (NASDAQ: QNCX) announced that its Board of Directors has unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital, which offered $1.60 per share in cash. The Board determined that the offer undervalues the company and is not aligned with the best interests of Quince and its shareholders. This decision underscores Quince's strategy to continue developing innovative therapeutics aimed at transforming patient lives. The company is actively pursuing opportunities to enhance its clinical pipeline with promising assets.
Quince Therapeutics, Inc. (Nasdaq: QNCX) has appointed MTS Health Partners, L.P. as its financial advisor to explore strategic alternatives aimed at maximizing long-term shareholder value. The review will emphasize opportunities in in-licensing and acquisitions, positioning Quince for potential growth.
Chairperson David Lamond highlighted the importance of this strategic review, stating a commitment to pursuing options that benefit all stockholders. The company has not guaranteed specific outcomes or timing from this process, indicating that further communication will only occur as deemed appropriate.
As a biotechnology firm, Quince is actively searching for innovative therapies to expand its development pipeline and improve the lives of patients with rare diseases.
Quince Therapeutics, Inc. (Nasdaq: QNCX) has approved a one-year stockholder rights plan to protect its interests following an unsolicited acquisition proposal. The plan includes a dividend distribution of one preferred share purchase right per share, effective April 17, 2023. The rights will be exercisable if any entity acquires 10% or more of the stock without Board approval, allowing existing stockholders to purchase shares at a favorable price, helping to prevent acquisition at lower premiums. The company is hiring a financial advisor to explore strategic alternatives, including in-licensing and acquisitions, aimed at maximizing long-term shareholder value. The plan is designed to ensure that all shareholders can realize the value of their investments.
Quince Therapeutics, Inc. (NASDAQ: QNCX) has received an unsolicited acquisition offer from Echo Lake Capital. The company’s Board of Directors is currently reviewing the proposal to ascertain the best course of action for its shareholders. Stockholders are advised that no action is required at this time. Quince Therapeutics is focused on acquiring and developing innovative therapeutics for rare diseases, actively seeking clinical-stage assets for its pipeline expansion.
Echo Lake Capital has proposed to acquire Quince Therapeutics (NASDAQ:QNCX) for $1.60 per share in cash, representing a 90% premium over the stock's closing price. The offer is compelling, considering Quince currently holds approximately $2.55 per share in cash and investments, with additional assets including potential milestone payments and federal net operating loss carryforwards. Notably, Quince is not actively developing or marketing any drugs, leading to concerns over its valuation and risk of delisting due to a 70% decline in stock price since its recent acquisition.
Quince Therapeutics, Inc. (NASDAQ: QNCX) has announced an update on its development pipeline and business strategy for 2023. The company aims to prioritize resources on acquiring clinical-stage assets targeting rare diseases and intends to out-license its bone-targeting drug platform and NOV004, an anabolic peptide for accelerated fracture repair. Quince holds approximately $94 million in cash, with a projected annual expenditure of around $11 million in 2023, ensuring a runway until at least 2028. The company is actively seeking partnerships to enhance its strategic growth and has completed all IND-enabling studies for NOV004, preparing for out-licensing by the end of 2023.
Quince Therapeutics (QNCX) has announced the sale of its legacy small molecule protease inhibitor portfolio to Lighthouse Pharmaceuticals. This portfolio includes compounds such as COR588, which targets Alzheimer's disease. Quince aims to offload these assets for strategic focus and operational efficiency. The deal could yield Quince up to $150 million in milestone payments, along with tiered royalties on sales. They will also receive a 7.5% ownership stake in Lighthouse. Additionally, Quince anticipates an annual expense reduction exceeding $500,000 linked to these assets.